or Try an Advanced Search...

    Technical Analysis for VSTM - Verastem, Inc.

    Grade Last Price % Change Price Change
    C 3.92 4.26% 0.16
    VSTM closed up 4.26 percent on Friday, November 1, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Nov 6
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical VSTM trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Up 5 Days in a Row Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Older End-of-Day Signals for VSTM ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    Upper Bollinger Band Resistance about 22 hours ago
    1.5x Volume Pace about 23 hours ago
    Up 5% about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    VSTM Chart by TradingView
    Basic chart:

    Profile

    Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The company's product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Oncology Stem Cell Breast Cancer Ovarian Cancer Treatment Of Breast Cancer Signal Transduction Cancer Research mTOR Companion Diagnostic Metastasis Advanced Cancer Mesothelioma Advanced Cancers Cancer Stem Cell Cancer Stem Cells Mtor Inhibitors

    Is VSTM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 1 Verastem Oncology submits NDA for ovarian cancer treatment
    Nov 1 Verastem Oncology completes rolling NDA submission to FDA for ovarian cancer treatment
    Oct 31 Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
    Oct 31 Verastem Oncology to Participate in Upcoming Investor Conferences
    Oct 17 Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
    Oct 9 Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
    Oct 7 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Sep 10 Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
    Sep 10 Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
    Sep 6 Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity
    See more VSTM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.22
    52 Week Low 2.1
    Average Volume 765,040
    200-Day Moving Average 6.78
    50-Day Moving Average 2.90
    20-Day Moving Average 3.25
    10-Day Moving Average 3.52
    Average True Range 0.28
    RSI (14) 67.43
    ADX 36.4
    +DI 33.82
    -DI 10.39
    Chandelier Exit (Long, 3 ATRs) 3.15
    Chandelier Exit (Short, 3 ATRs) 3.39
    Upper Bollinger Bands 3.91
    Lower Bollinger Band 2.58
    Percent B (%b) 1.0
    BandWidth 41.03
    MACD Line 0.24
    MACD Signal Line 0.18
    MACD Histogram 0.0638
    Fundamentals Value
    Market Cap 99.05 Million
    Num Shares 25.3 Million
    EPS -3.89
    Price-to-Earnings (P/E) Ratio -1.01
    Price-to-Sales 51.84
    Price-to-Book 4.01
    PEG Ratio -1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.27
    Resistance 3 (R3) 4.25 4.13 4.21
    Resistance 2 (R2) 4.13 4.04 4.13 4.19
    Resistance 1 (R1) 4.02 3.98 4.08 4.04 4.17
    Pivot Point 3.90 3.90 3.92 3.90 3.90
    Support 1 (S1) 3.79 3.81 3.85 3.81 3.67
    Support 2 (S2) 3.67 3.75 3.67 3.65
    Support 3 (S3) 3.56 3.67 3.63
    Support 4 (S4) 3.58